Role of tolvaptan in acute decompensated heart failure

References

• Fonarow GC, Corday E. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail. Rev.9(3), 179–185 (2004).
   PubMed Web of Science ®Google Scholar
• Francis GS, Benedict C, Johnstone DE et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation82(5), 1724–1729 (1990).
   PubMed Web of Science ®Google Scholar
• Domanski M, Norman J, Pitt B et al. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol.42(4), 705–708 (2003).
   PubMed Web of Science ®Google Scholar
• Philbin EF, Cotto M, Rocco TA Jr, Jenkins PL. Association between diuretic use, clinical response, and death in acute heart failure. Am. J. Cardiol.80(4), 519–522 (1997).
   PubMed Web of Science ®Google Scholar
• De Luca L, Orlandi C, Udelson JE, Fedele F, Gheorghiade M. Overview of vasopressin receptor antagonists in heart failure resulting in hospitalization. Am. J. Cardiol.96(12A), L24–L33 (2005).
   Google Scholar
• Klein L, O’Connor CM, Leimberger JD et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation111(19), 2454–2460 (2005).
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA293(5), 572–580 (2005).
   PubMed Web of Science ®Google Scholar
• Yancy C. Climbing the mountain of acute decompensated heart failure: the EVEREST trials. JAMA297(12), 1374–1376 (2007).
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Massie BM. Nesiritide and worsening of renal function: the emperor’s new clothes? Circulation111(12), 1459–1461 (2005).
   PubMed Web of Science ®Google Scholar
• Elkayam U, Tasissa G, Binanay C et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am. Heart J.153(1), 98–104 (2007).
   PubMed Web of Science ®Google Scholar
• Weber KT. Furosemide in the long-term management of heart failure: the good, the bad, and the uncertain. J. Am. Coll. Cardiol.44(6), 1308–1310 (2004).
   PubMed Web of Science ®Google Scholar
• Felker GM, Benza RL, Chandler AB et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J. Am. Coll. Cardiol.41(6), 997–1003 (2003).
   PubMed Web of Science ®Google Scholar
• Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation111(12), 1487–1491 (2005).
   PubMed Web of Science ®Google Scholar
• Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA293(15), 1900–1905 (2005).
   PubMed Web of Science ®Google Scholar
• Aaronson KD, Sackner-Bernstein J. Risk of death associated with nesiritide in patients with acutely decompensated heart failure. JAMA296(12), 1465–1466 (2006).
   PubMed Web of Science ®Google Scholar
• Costanzo MR, Guglin ME, Saltzberg MT et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J. Am. Coll. Cardiol.49(6), 675–683 (2007).
   PubMed Web of Science ®Google Scholar
• Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur. J. Heart Fail.8(1), 105–110 (2006).
   PubMed Web of Science ®Google Scholar
• Follath F, Cleland JG, Just H et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet360(9328), 196–202 (2002).
   PubMed Web of Science ®Google Scholar
• Packer M, Colucci WS, Fisher L et al. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure results with levosimendan in the REVIVE-1 study [abstract]. J. Card. Fail.9, S61 (2003).
   Google Scholar
• Mebazaa A, Nieminen MS, Packer M et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA297(17), 1883–1891 (2007).
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Teerlink JR, Cotter G et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA298(17), 2009–2019 (2007).
   PubMed Web of Science ®Google Scholar
• Rouleau JL, Packer M, Moye L et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J. Am. Coll. Cardiol.24(3), 583–591 (1994).
   PubMed Web of Science ®Google Scholar
• Palm C, Pistrosch F, Herbrig K, Gross P. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia. Am. J. Med.119(7 Suppl. 1), S87–S92 (2006).
   PubMedGoogle Scholar
• Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J. Am. Coll. Cardiol.46(10), 1785–1791 (2005).
   PubMed Web of Science ®Google Scholar
• Udelson JE, Smith WB, Hendrix GH et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation104(20), 2417–2423 (2001).
   PubMed Web of Science ®Google Scholar
• Yamamura Y, Nakamura S, Itoh S et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J. Pharmacol. Exp. Ther.287(3), 860–867 (1998).
   PubMed Web of Science ®Google Scholar
• Shoaf SE, Wang Z, Bricmont P, Mallikaarjun S. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide avp antagonist, during ascending single-dose studies in healthy subjects. J. Clin. Pharmacol.47(12), 1498–1507 (2007).
   PubMed Web of Science ®Google Scholar
• Costello-Boerrigter L, Smith W, Boerrigter G et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am. J. Physiol. Renal Physiol.290(2), F273–F278 (2006).
   PubMed Web of Science ®Google Scholar
• Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N. Engl. J. Med.341(8), 577–585 (1999).
   PubMed Web of Science ®Google Scholar
• Robinson A, Verbalis J. Posterior pituitary. In: Williams Textbook of Endocrinology (11th Edition). Kronenberg HM (Ed.). Saunders Elsevier, PA, USA, 264 (2008).
   Google Scholar
• Xu YJ, Gopalakrishnan V. Vasopressin increases cytosolic free [Ca2+] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors. Circ. Res.69(1), 239–245 (1991).
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Haneda T, Osaki J, Miyata S, Kikuchi K. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. Eur. J. Pharmacol.391(1–2), 39–48 (2000).
   PubMed Web of Science ®Google Scholar
• Walker BR, Childs ME, Adams EM. Direct cardiac effects of vasopressin: role of V1- and V2-vasopressinergic receptors. Am. J. Physiol.255(2 Pt 2), H261–H265 (1988).
   Web of Science ®Google Scholar
• Kondo K, Ogawa H, Yamashita H et al. 7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist. Bioorg. Med. Chem.7(8), 1743–1754 (1999).
   PubMed Web of Science ®Google Scholar
• Hauptman P, Zimmer C, Udelson J et al. Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure. J. Cardiovasc. Pharmacol.46(5), 609–614 (2005).
   PubMed Web of Science ®Google Scholar
• Burnett J, Smith W, Ouyang J, Zimmer C, Orlandi C. Tolvaptan (OPC-41061), a V2 vasopressin antacgonist protects against the decline in renal function observed with loop diuretic therapy. J. Card. Fail.9, 36 (2003).
   PubMed Web of Science ®Google Scholar
• Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J. Pharmacol. Exp. Ther.292(1), 288–294 (2000).
   PubMed Web of Science ®Google Scholar
• Shoaf SE, Bramer SL, Bricmont P, Zimmer CA. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide. J. Cardiovasc. Pharmacol.50(2), 213–222 (2007).
   PubMed Web of Science ®Google Scholar
• Shoaf SE, Elizari MV, Wang Z et al. Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias. J. Cardiovasc. Pharmacol. Ther.10(3), 165–171 (2005).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Niazi I, Ouyang J et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation107(21), 2690–2696 (2003).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Gattis W, O’Connor C et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA291(16), 1963–1971 (2004).
   PubMed Web of Science ®Google Scholar
• Udelson J, McGrew F, Flores E et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J. Am. Coll. Cardiol.49(22), 2151–2159 (2007).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Gattis W, Barbagelata A et al. Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Am. Heart J.145(2 Suppl.), S51–S54 (2003).
   PubMed Web of Science ®Google Scholar
• Rossi J, Bayram M, Udelson J et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card. Care9(2), 82–86 (2007).
   PubMedGoogle Scholar
• Gheorghiade M, Gottlieb S, Udelson J et al. Vasopressin V(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am. J. Cardiol.97(7), 1064–1067 (2006).
   PubMed Web of Science ®Google Scholar
• Udelson J, Orlandi C, Ouyang J et al. Acute hemodynamic effects of tolvaptan, a vasopressin v2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: the ECLIPSE international, multicenter, randomized, placebo-controlled trial. J. Card. Fail.13(9), 793–794 (2007).
   Google Scholar
• Schrier R, Gross P, Gheorghiade M et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med.355(20), 2099–2112 (2006).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Orlandi C, Burnett J et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J. Card. Fail.11(4), 260–269 (2005).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Konstam M, Burnett J et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA297(12), 1332–1343 (2007).
   PubMed Web of Science ®Google Scholar
• Konstam M, Gheorghiade M, Burnett J et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA297(12), 1319–1331 (2007).
   PubMed Web of Science ®Google Scholar
• Kondo K, Ogawa H, Yamashita H et al. 7-chloro-5-hydroxy-1- [2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1h-1-benzazepine (opc-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist. In: Bioorganic & Medicinal Chemistry. Elsevier, NJ, USA, 12 (1999).
   Google Scholar